Literature DB >> 12054849

Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition.

Koichi Kaikita1, John A Schoenhard, Corrie A Painter, Robert T Ripley, Nancy J Brown, Agnes B Fogo, Douglas E Vaughan.   

Abstract

Recent studies have indicated that a number of factors contribute to the pathophysiology in response to nitric oxide synthase (NOS) inhibition. We previously demonstrated that plasminogen activator inhibitor-1 deficient (PAI-1-/-) mice are protected against hypertension and perivascular fibrosis induced by relatively short-term NOS inhibition. In this study, we compared the temporal changes in systolic blood pressure and coronary perivascular fibrosis induced by long-term treatment with N(omega)-nitro- L -arginine methyl ester (L -NAME) in wild type (WT), PAI-1(-/-) and tissue-type plasminogen activator deficient (t-PA-/-) mice. After initiating L -NAME, systolic blood pressure increased in all groups at 2 weeks. Over a 16 week study period, systolic blood pressure increased to 143+/-3 mmHg (mean+/-SEM) in WT animals, 139+/-2 in t-PA-/- mice vs 129+/-2 in PAI-1-/- mice (P < 0.01). Coronary perivascular fibrosis increased in L -NAME-treated WT and t-PA(-/-) mice compared to each control group (P<0.01 in WT, P<0.05 in t-PA-/-), while PAI-1-/- mice were protected against fibrosis induced by L -NAME. t-PA deficiency did not accentuate the vascular pathology or the changes in blood pressure. In situ zymography demonstrated augmented gelatinolytic activity in PAI-1-/- mice at baseline, suggesting that PAI-1 deficiency prevents the increase of collagen deposition by promoting matrix degradation. Plasma TGF-beta1 levels increased in L -NAME-treated WT and PAI-1-/- mice (P < 0.01), but not in L -NAME-treated t-PA-/- mice. These findings support the hypothesis that the plasminogen activator system protects against the structural vascular changes induced by long-term NOS inhibition. While PAI-1 deficiency protects against L -NAME-induced hypertension and perivascular fibrosis, t-PA deficiency does not exacerbate the vascular pathology or hypertension. Copyright 2002 Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12054849     DOI: 10.1006/jmcc.2002.2001

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  12 in total

Review 1.  Modulation of glomerulosclerosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2007-09-08       Impact factor: 9.623

2.  Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo.

Authors:  Mehmet Agirbasli; Mesut Eren; Songul Yasar; Kenan Delil; Fatih Goktay; Ebru Toksoy Oner; Douglas E Vaughan
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

3.  Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling.

Authors:  Yumei Zhan; Courtney Brown; Elizabeth Maynard; Aleksandra Anshelevich; Weihua Ni; I-Cheng Ho; Peter Oettgen
Journal:  J Clin Invest       Date:  2005-09       Impact factor: 14.808

4.  PAI-1 antagonists: the promise and the peril.

Authors:  Douglas E Vaughan
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

5.  Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy.

Authors:  Mehmet Agirbasli; Mesut Eren; Fatih Eren; Sheila B Murphy; Zehra A Serdar; Dilek Seckin; Tuba Zara; M Cem Mat; Cuyan Demirkesen; Douglas E Vaughan
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

6.  Relationship between plasma plasminogen activator inhibitor-1 and hypertension in American Indians: findings from the Strong Heart Study.

Authors:  Hao Peng; Fawn Yeh; Giovanni de Simone; Lyle G Best; Elisa T Lee; Barbara V Howard; Jinying Zhao
Journal:  J Hypertens       Date:  2017-09       Impact factor: 4.844

7.  Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.

Authors:  Amanda E Boe; Mesut Eren; Sheila B Murphy; Christine E Kamide; Atsuhiko Ichimura; David Terry; Danielle McAnally; Layton H Smith; Toshio Miyata; Douglas E Vaughan
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

Review 8.  Functional stability of plasminogen activator inhibitor-1.

Authors:  Songul Yasar Yildiz; Pinar Kuru; Ebru Toksoy Oner; Mehmet Agirbasli
Journal:  ScientificWorldJournal       Date:  2014-10-15

9.  Nitric oxide prevents alveolar senescence and emphysema in a mouse model.

Authors:  Amanda E Boe; Mesut Eren; Luisa Morales-Nebreda; Sheila B Murphy; G R Scott Budinger; Gökhan M Mutlu; Toshio Miyata; Douglas E Vaughan
Journal:  PLoS One       Date:  2015-03-10       Impact factor: 3.240

Review 10.  PAI-1 and kidney fibrosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.